What Abdera Therapeutics does

Abdera Therapeutics is a Vancouver-based, privately held oncology company founded in 2021 that develops targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. The company's lead programs are antibody-based radiopharmaceuticals built on its proprietary ROVEr platform, which is engineered to optimize radioisotope delivery to tumor cells. The disclosed pipeline centers on ABD-147, a DLL3-targeted radiotherapeutic for small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), and ABD-320, a pan-cancer radiotherapeutic candidate.

The ROVEr platform is the core technology asset and the basis for differentiation versus other TAT developers such as Ratio Therapeutics and Perspective Therapeutics. Abdera operates pre-clinically as of early 2026 and has no commercial products, pricing, or distribution infrastructure; the intended commercial model aligns with licensing/royalty economics typical of asset-light radiopharma developers. The company emerged publicly in April 2023 with a $142 million combined Series A and Series B financing led by venBio Partners, with Versant Ventures, Viking Global Investors, RTW Investments, Qiming Venture Partners USA, Amplitude Venture Capital, and Northview LifeSciences participating, following a roughly $6.3 million seed in 2021.

Go-to-market is presently limited to scientific and investor-facing channels, including pipeline presentations at industry conferences such as the 44th Annual J.P. Morgan Healthcare Conference in January 2026 by CEO Lori Lyons-Williams. The company has 51–100 employees and remains an independent private entity with no disclosed parent, subsidiaries, partnerships, M&A activity, or regulatory actions on record.

Name

Abdera Therapeutics

Legal name

Abdera Therapeutics

Website

https://abderatherapeutics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

51–100 employees

Short description

Abdera Therapeutics is a Vancouver-based, privately held oncology biotech developing targeted alpha radiopharmaceuticals using its proprietary ROVEr antibody platform to treat DLL3-expressing cancers, with lead candidate ABD-147 in small cell lung cancer.

Ownership category

akta.pro rank

Product category

Oncology Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• Targeted radiopharmaceuticals
• Oncology drug development
• Antibody-radionuclide conjugates
• Targeted alpha therapy
• DLL3 cancer therapeutics

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Radiopharmaceutical Development: Pre-commercial stage company developing antibody-based radiopharmaceuticals for cancer treatment. No revenue currently generated as products are in pre-clinical stages.

Marketing channels1 record

Core offering

Abdera Therapeutics develops antibody-based radiopharmaceuticals for the treatment of cancer, leveraging its proprietary ROVEr platform to optimize radioisotope delivery to tumor cells. The company's pipeline includes ABD-147, which targets DLL3 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), and ABD-320, a pan-cancer radiotherapeutic candidate. The company is currently in the pre-clinical stage of drug development.

Product overview

Abdera Therapeutics is a biotech company developing targeted radiopharmaceuticals for cancer treatment using its proprietary ROVEr platform. The company's lead pipeline includes ABD-147 (targeting DLL3 for small cell lung cancer and LCNEC) and ABD-320 (with pan-cancer potential), both antibody-based radiotherapeutics designed to optimize radioisotope delivery to tumor cells.

Differentiator

Problem solved

Functional benefit

Products and services

• ROVEr Platform A proprietary technology platform for developing antibody-based radiopharmaceuticals for cancer treatment, designed to optimize radioisotope delivery to tumor cells. It underpins Abdera's pipeline of antibody-radionuclide conjugates.
• ABD-147 A radiotherapeutic candidate in Abdera's pipeline targeting DLL3 for the treatment of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). It is being developed using the company's ROVEr platform to optimize antibody-based radioisotope delivery.
• ABD-320 A radiotherapeutic candidate with pan-cancer potential, in development for multiple oncology indications beyond SCLC and LCNEC as part of Abdera's pipeline of antibody-based targeted radiopharmaceuticals built on the ROVEr platform.

Quantifiable outcome

• DLL3-targeted therapy development for SCLC and LCNEC

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Expansion highlights4 records

Broad incumbents

• Novartis (Radioligand Therapy): Owner of Pluvicto and Lutathera, the commercial benchmarks in radioligand therapy. The dominant incumbent whose commercial traction and pipeline expansion define the strategic context for every peer including Abdera.
• Lantheus Holdings: Radiopharmaceutical-focused specialty company with approved diagnostic and therapeutic agents (e.g., PNT2002 prostate cancer program). A broad incumbent in the targeted radiopharmaceutical space.
• Bayer (Radiopharmaceuticals): Developer of Xofigo (radium-223) and active builder of a broader targeted radionuclide therapy pipeline. A broad incumbent with strategic interest in TATs comparable to Abdera's approach.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals across oncology indications. A broader incumbent with overlapping development priorities.

Others

• ITM Isotope Technologies Munich: Manufacturer and supplier of medical radioisotopes (including actinium-225) used in targeted radionuclide therapy. An ecosystem enabler whose supply chain underpins the entire radiopharmaceutical class including Abdera's pipeline.

Direct peers

• Perspective Therapeutics: Pre-clinical-stage radiopharmaceutical company developing targeted alpha therapies for solid tumors. Explicitly named as a same-stage competitor to Abdera with overlapping therapeutic focus.
• Ratio Therapeutics: Pre-clinical developer of radiopharmaceuticals (including Radioligand Therapy platform technologies) targeting oncology. Explicitly cited alongside Abdera at the same development stage with overlapping lung cancer and pan-tumor ambitions.
• RayzeBio: Pre-clinical/clinical-stage developer of actinium-225 alpha-emitting radiopharmaceuticals for oncology. Acquired by Bristol Myers Squibb for $4.1 billion; the most direct comparable for Abdera's TAT platform.

Emerging players

• Mariana Oncology: Radiopharmaceutical-focused oncology platform company acquired by Novartis in 2024 for $1 billion upfront. Develops peptide-based radioligand therapies; comparable as a platform-approach targeted radiopharmaceutical developer.
• Convergent Therapeutics: Clinical-stage radiopharmaceutical company developing targeted alpha therapy for PSMA-expressing cancers; acquired by Eli Lilly in 2024. Comparable as a TAT-focused oncology developer with similar therapeutic modality to Abdera.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/abdera_thera
• LinkedInlinkedin.com/company/abdera-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abdera Therapeutics